MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,OIL28	SA00046908	45	F	SA00046908
Ordering Phys				**DOB** 06/10/1966
Client Order # SA00046908	**Account Information**			**Report Notes**
Collected 06/03/2012 13:00	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
Printed 06/19/2012 15:17				

Test	Flag	Results	Unit	Reference Value	Perform Site*
Rapid DNA Extraction, Saliva			REPORTED 06/04/2012 10:46		
Comment		See Below			MCR
Result: Genomic DNA was extracted.					
IL28B Polymorphism Genotype, Saliva			REPORTED 06/04/2012 08:56		
IL28B Polymorphism Genotype		CT			MCR
IL28B Interpretation					MCR
IL28B-related rs12979860 CT genotype has been associated with a poorer viral response in HCV genotype 1-infected individuals treated with combined pegylated-interferon and ribavirin therapy as compared to CC genotypes. Individuals with the CC genotype, which is not the situation for this patient, have approximately a 2- to 3-fold greater rate of sustained virologic response (SVR) in HCV genotype 1-infected individuals treated with combined pegylated interferon and ribavirin therapy as compared to either the CT or TT genotypes. Similar SVR have been observed across various racial groups including European Americans, African Americans, and Hispanics. CC genotype has also been associated with a 3-fold increase in rate of spontaneous clearance of HCV. IL28B genotype is only one of many factors that can influence response related to pegylated interferon/ribavirin combination therapy in HCV genotype 1 infection and should be interpreted in the context of other clinical factors.					
Direct polymorphism analysis of the IL28B-related rs12979860 polymorphism is performed by a Polymerase Chain Reaction (PCR) based 5'-nuclease assay using fluorescently labeled detection probes. This DNA testing will not detect all the known mutations and polymorphisms of IL28B. Absence of mention of a specific gene mutation or polymorphism does not rule out the possibility that a patient has that or another variation that can impact the function of this receptor, drug response or drug side effects.					
Laboratory developed test.					
Reviewed by		Jamie Bruflat			MCR

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT,OIL28	06/03/2012 13:00	Final
Page 1 of 1		** End of Report **

* Report times for Mayo performed tests are CST/CDT

TEST SITE